WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017182706) DIAGNOSIS OF IMMUNE_ACTIVATION USING CLEVER-1, TNF-ALPHA AND HLA-DR BINDING AGENTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/182706    International Application No.:    PCT/FI2017/050286
Publication Date: 26.10.2017 International Filing Date: 18.04.2017
IPC:
C07K 16/28 (2006.01), G01N 33/50 (2006.01), A61K 39/00 (2006.01)
Applicants: FARON PHARMACEUTICALS OY [FI/FI]; Joukahaisenkatu 6 20520 Turku (FI)
Inventors: HOLLMÉN, Maija-Leena; (FI).
VIITALA, Miro; (FI).
JALKANEN, Markku; (FI).
MAKSIMOW, Mikael; (FI)
Agent: BERGGREN OY; P.O. Box 99 Tykistökatu 2-4 B FI-20521 Turku (FI)
Priority Data:
20165336 18.04.2016 FI
Title (EN) DIAGNOSIS OF IMMUNE_ACTIVATION USING CLEVER-1, TNF-ALPHA AND HLA-DR BINDING AGENTS
(FR) DIAGNOSTIC DE L'ACTIVATION IMMUNITAIRE À L'AIDE D'AGENTS DE LIAISON À CLEVER-1, AU TNF-ALPHA ET À HLA-DR
Abstract: front page image
(EN)An agent capable of binding to CLEVER-1 in an individual can be used in activating macrophages to switch their phenotype from M2 macrophages into M1 macrophages. The invention relates to methods for utilizing the macrophages ability to switch their phenotype. In one aspect, the invention relates to a method for estimating of the efficacy of anti-CLEVER-1 therapy by monitoring a modulation of M2 macrophages into M1 macrophages, when an agent capable of binding to CLEVER-1 is administered in a patient, wherein an increased TNF-alpha secretion or HLA-DR expression is indicative of modulation of M2 macrophages into M1 macrophages.
(FR)Un agent capable de se lier à CLEVER-1 chez un individu peut être utilisé pour activer des macrophages pour commuter leur phénotype de macrophages M2 en macrophages M1. L'invention concerne des procédés d'utilisation de la capacité des macrophages à commuter leur phénotype. Dans un aspect, l'invention concerne un procédé d'estimation de l'efficacité d'une thérapie anti-CLEVER-1 par suivi d'une modulation de macrophages M2 en macrophages M1, lorsqu'un agent capable de se lier à CLEVER-1 est administré à un patient, une sécrétion augmentée de TNF-alpha ou une expression augmentée de HLA-DR étant indicatrice de la modulation de macrophages M2 en macrophages M1.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)